Skip to main content

Table 5 Dose-volume analysis of 4 major late complications

From: Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment

Complications

OAR volume

EBRT dose

SBRT dose

EBRT D30%

EBRT D50%

SBRT Dmax at OAR

SBRT D10%

SBRT D30%

SBRT D50%

SBRT V50%

SBRT V70%

 

(cc)

(Gy)

(Gy/Fx)

(Gy)

(Gy)

(Gy)

(Gy)

(Gy)

(Gy)

(%)

(%)

Pontine necrosis (Brainstem)

1

24.67

59.4

25/5

43.5

40.9

24.6

19

15.4

12.8

23.5

0.7

2

23.55

55.8

21/3

36.2

19.7

27.3

24.2

20.1

16.0

54.3

24.9

Temporal lobe necrosis (Temporal lobe)

1

63

45

25/5

48.1

45.3

28.4

17.9

10.3

6.2

11.2

4.4

2

66.02

70.2

21/3

37.4

11.7

25.0

16.5

8.9

4.9

18.8

5.7

Optic retinopathy (Eyeball)

1

10.7

45

25/5

45.1

45.1

27.7

23.7

18.4

13.3

35.9

12.8

2

11.2

50.4

20/5

52.1

49

22.5

21.1

18

13.5

50.6

25.9

Optic neuropathy (Optic nerve)

1

0.483

45

25/5

41.3

40.7

27.8

27.3

27.0

26.7

100

97.2

  1. OAR, organ at risk; EBRT, external beam radiotherapy; SBRT, stereotactic body radiotherapy; Fx, fraction; Dx%, dose covering x% of total volume; Dmax, maximum dose; Vx%, volume receiving x% of prescribed dose.